Rockwell Medical (NASDAQ: RMTI) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Rockwell Medical and AbbVie, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rockwell Medical 1 0 1 1 2.67
AbbVie 0 6 7 0 2.54

Rockwell Medical presently has a consensus price target of $9.33, suggesting a potential upside of 38.48%. AbbVie has a consensus price target of $83.75, suggesting a potential downside of 4.19%. Given Rockwell Medical’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Rockwell Medical is more favorable than AbbVie.

Risk and Volatility

Rockwell Medical has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.

Profitability

This table compares Rockwell Medical and AbbVie’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rockwell Medical -39.68% -42.22% -27.15%
AbbVie 24.77% 150.27% 12.52%

Dividends

AbbVie pays an annual dividend of $2.56 per share and has a dividend yield of 2.9%. Rockwell Medical does not pay a dividend. AbbVie pays out 62.9% of its earnings in the form of a dividend. AbbVie has raised its dividend for 44 consecutive years.

Earnings & Valuation

This table compares Rockwell Medical and AbbVie’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Rockwell Medical $54.04 million 6.45 -$21.07 million ($0.42) -16.05
AbbVie $26.71 billion 5.22 $11.57 billion $4.07 21.48

AbbVie has higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

21.4% of Rockwell Medical shares are held by institutional investors. Comparatively, 68.3% of AbbVie shares are held by institutional investors. 15.9% of Rockwell Medical shares are held by insiders. Comparatively, 0.2% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

AbbVie beats Rockwell Medical on 10 of the 17 factors compared between the two stocks.

About Rockwell Medical

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.

About AbbVie

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.